Home/ Stocks/ IRD

Opus Genetics, Inc. Common Stock

IRD XNAS

$3.66 -0.18 (-4.95%) ▼ 15-min delayed

Open

$3.73

High

$3.75

Low

$3.52

Volume

915.2K

Market Cap

$307.14M

About Opus Genetics, Inc. Common Stock

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 28 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.16M	$-65,535,000	$-0.75
FY 2025	$14.20M	$-49,591,000	$-0.80
Q3 2025	$3.08M	$-17,454,000	$-0.25
Q1 2025	$4.37M	$-8,194,000	$-0.24

Related Market News

No specific coverage for IRD yet. Check out our latest market news or earnings calendar.

Get IRD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Opus Genetics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.